Nurix Therapeutics (NRIX) Q3 2026 Earnings
Includes $653.2 million of one-time license revenue recognized from the Roche collaboration and $34.4 million in one-time G&A expenses for Roche transaction consulting and business development costs
How Did NRIX Stock React to Q3 2026 Earnings?
Did NRIX Beat Earnings? Q3 2026 Results
No. Nurix Therapeutics reported Q3 2026 earnings of $4.73 a share on Oct 13, 2026, missing the $5.11 consensus estimate by 7.5%. Revenue was $673.1M against a $479.5M estimate.
Nurix Therapeutics posted a revenue beat but an earnings miss in fiscal Q3 2026, as a transformational collaboration with Roche reshaped the company's financial profile almost overnight. Revenue surged to $673.06 million from just $7.89 million a year ago, a gain of 8,426.3% that cleared the $479.52 million consensus estimate by 40.36%, with $653.16 million of that total tied to one-time license revenue recognized from the Roche deal for bexobrutideg. GAAP earnings per diluted share came in at $4.73, which includes that $653.2 million in one-time license revenue as well as $34.4 million in one-time consulting and business development costs tied to the transaction; even so, the result fell 7.50% short of the $5.11 consensus. The company swung to net income of $549.81 million from a loss of $86.42 million in the prior-year period. With roughly $1.10 billion in cash now on hand, Nurix has guided runway into the second half of 2029, while the registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg against pirtobrutinib advances as the program's central near-term catalyst.
- $653.2 million license revenue from Roche collaboration drove revenue surge
- $10 million Sanofi milestone for first patient dosed in STAT6 degrader Phase 1 trial
- $7 million Pfizer milestone achievement
- $10 million one-time fee from Gilead for research term extension
- R&D expense reduction from Roche cost-sharing offset
“The third quarter marked an important transition for Nurix as we moved bexobrutideg into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto-immune disease.”
Nurix Therapeutics CEO, on the earnings call
What Is Nurix Therapeutics's Outlook?
Nurix has approximately $1.1 billion in cash, cash equivalents and marketable securities providing runway into the second half of 2029. The company is executing a broad clinical development strategy for bexobrutideg spanning multiple hematologic malignancies, combination approaches in CLL, and expansion into immune-mediated diseases including chronic spontaneous urticaria (CSU) and multiple sclerosis (MS). Development costs for bexobrutideg are shared 40% by Nurix and 60% by Roche, with equal U.S. profit/loss sharing and tiered royalties on ex-U.S. sales. NX-1607 expansion cohorts across four solid tumor indications are each planned to enroll approximately 30 patients. Nurix remains eligible to receive approximately $455 million in future development, regulatory, and commercial milestones from Sanofi for the STAT6 program, plus potential royalties.
NRIX YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $673.1M | $7.9M | +8,426.3% |
| Operating Income | $559.5M | $68.9M | +712.2% |
| Net Income | $549.8M | $65.8M | +736.2% |
NRIX Revenue by Segment
When Does Nurix Therapeutics Report Next?
Figures from SEC filings and company reports. Not investment advice.